212 related articles for article (PubMed ID: 35771152)
1. TRPM7 via calcineurin/NFAT pathway mediates metastasis and chemotherapeutic resistance in head and neck squamous cell carcinoma.
Chen TM; Huang CM; Hsieh MS; Lin CS; Lee WH; Yeh CT; Liu SC
Aging (Albany NY); 2022 Jun; 14(12):5250-5270. PubMed ID: 35771152
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
3. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma.
St John MA
Laryngoscope; 2015 Mar; 125 Suppl 3():S1-11. PubMed ID: 25646683
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition and cancer stem cells: A route to acquired cisplatin resistance through epigenetics in HNSCC.
Lima de Oliveira J; Moré Milan T; Longo Bighetti-Trevisan R; Fernandes RR; Machado Leopoldino A; Oliveira de Almeida L
Oral Dis; 2023 Jul; 29(5):1991-2005. PubMed ID: 35403781
[TBL] [Abstract][Full Text] [Related]
6. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
8. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
9. Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Ma SR; Wang WM; Huang CF; Zhang WF; Sun ZJ
Oncotarget; 2015 Apr; 6(11):8807-21. PubMed ID: 25871396
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S
Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886
[TBL] [Abstract][Full Text] [Related]
11. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
12. Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.
Wu YC; Huang CS; Hsieh MS; Huang CM; Setiawan SA; Yeh CT; Kuo KT; Liu SC
Aging (Albany NY); 2024 Jan; 16(1):627-647. PubMed ID: 38206305
[TBL] [Abstract][Full Text] [Related]
13. Pluripotency transcription factor Nanog and its association with overall oral squamous cell carcinoma progression, cisplatin-resistance, invasion and stemness acquisition.
Kashyap T; Nath N; Mishra P; Jha A; Nagini S; Mishra R
Head Neck; 2020 Nov; 42(11):3282-3294. PubMed ID: 32710593
[TBL] [Abstract][Full Text] [Related]
14. Multi-Omics Identification of Genetic Alterations in Head and Neck Squamous Cell Carcinoma and Therapeutic Efficacy of HNC018 as a Novel Multi-Target Agent for c-MET/STAT3/AKT Signaling Axis.
Khedkar HN; Chen LC; Kuo YC; Wu ATH; Huang HS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373393
[TBL] [Abstract][Full Text] [Related]
15. Transient receptor potential melastatin 7-like current in human head and neck carcinoma cells: role in cell proliferation.
Jiang J; Li MH; Inoue K; Chu XP; Seeds J; Xiong ZG
Cancer Res; 2007 Nov; 67(22):10929-38. PubMed ID: 18006838
[TBL] [Abstract][Full Text] [Related]
16. Integrative analyses of biomarkers and pathways for metformin reversing cisplatin resistance in head and neck squamous cell carcinoma cells.
Shanchun H; You P; Sujuan N; Xuebing Z; Yijie B; Xiaohui X; Jianming H; La N; Zhehui B; Qi L; Wulong J
Arch Oral Biol; 2023 Mar; 147():105637. PubMed ID: 36738487
[TBL] [Abstract][Full Text] [Related]
17. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
18. Snail-induced EMT promotes cancer stem cell-like properties in head and neck cancer cells.
Ota I; Masui T; Kurihara M; Yook JI; Mikami S; Kimura T; Shimada K; Konishi N; Yane K; Yamanaka T; Kitahara T
Oncol Rep; 2016 Jan; 35(1):261-6. PubMed ID: 26498709
[TBL] [Abstract][Full Text] [Related]
19. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
